Crossing the mucus barrier

A team from The Johns Hopkins University has shown that vaginal delivery of antiviral-loaded, mucus-penetrating particles can help prevent herpes simplex virus infection in mice.¹ The team thinks the particles have potential utility in infection, cancer, inflammation and other diseases that affect mucosal tissues in the eyes, sinuses, female reproductive tract, respiratory tract and GI tract.

Kala Pharmaceuticals Inc. is the exclusive worldwide licensee of the IP from Johns Hopkins University and is using the technology to develop improved treatments for mucosal tissue diseases, including cystic fibrosis (CF), severe ocular inflammation and ulcerative colitis...